Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: March 2024

MissionIRNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Financial Results, Corporate Highlights for Q4, FY 2023

Posted on March 21, 2024 by MissionIR

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced its financial numbers and operational highlights for the fourth quarter and full year ended Dec. 31, 2023. According to the … Continue reading →

Posted in HeartBeam Inc. BEAT | Leave a comment

MissionIRNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Continuing to Redefine Logistics Landscape with Innovative Solutions

Posted on March 21, 2024 by MissionIR

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) is a technology company whose custom-developed, industry-leading Fr8App freight-matching platform offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region. The company has been Riisa’s trusted logistics supplier for over two … Continue reading →

Posted in Freight Technologies Inc. FRGT | Leave a comment

Diamond Lake Minerals Inc. (DLMI) Announces Investment in Avrio Worldwide PBC Amidst Avrio’s Acquisition of HUMBL and SocialTrader

Posted on March 21, 2024 by MissionIR

Diamond Lake Minerals (OTC: DLMI), a multi-strategy operating company on a path to emerging as a pioneering force in the development of digital assets and SEC-registered security tokens, recently announced a strategic investment into Avrio Worldwide PBC, purchasing a 24% … Continue reading →

Posted in Diamond Lake Minerals Inc. DLMI | Leave a comment

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium

Posted on March 21, 2024 by MissionIR

Researchers used to believe that autism spectrum disorder only affected one in 2,500 children – today, that estimation is closer to one in 36 children. Between 1998 and 2018, research has found more than a 780% increase in the number … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS) Announces Go-to-Market Growth Strategy and Upcoming Participation in 36th Annual Roth Conference

Posted on March 21, 2024 by MissionIR

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently launched a new go-to-market (“GTM”) growth strategy to accelerate the adoption and deployment of commercial quantum technologies. … Continue reading →

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss; Sets Stage for 8-week Diabetes and Weight Loss Animal Study

Posted on March 21, 2024 by MissionIR

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released highlights from its DIAB-A22-1 animal study on rodents. The study sought to explore the overall efficiency of its patented DehydraTECH(TM)-CBD formulation and its impact on conditions associated … Continue reading →

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Why Zoned Properties Inc. (ZDPY) Is ‘One to Watch’

Posted on March 20, 2024 by MissionIR

Zoned Properties (OTCQB: ZDPY), a technology-driven property investment company for emerging and highly regulated industries, is focused on acquiring value-add real estate within the U.S. regulated cannabis industry. “The company aspires to innovate, focusing on direct-to-consumer real estate that is … Continue reading →

Posted in Zoned Properties Inc. ZDPY | Leave a comment

MissionIRNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

Posted on March 20, 2024 by MissionIR

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder (“ASD”), for which there is no approved pharmacologic treatment targeting cause and symptoms. “The current … Continue reading →

Posted in PaxMedica Inc. PXMD | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Info on $6.5M Registered Direct Offering

Posted on March 20, 2024 by MissionIR

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded … Continue reading →

Posted in Genprex Inc. GNPX | Leave a comment

MissionIRNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split

Posted on March 20, 2024 by MissionIR

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock. The move was approved by the company’s board of directors during a special … Continue reading →

Posted in Longeveron Inc. LGVN | Leave a comment